- Poster presentation
- Open Access
Cardiovascular risk estimation in Spanish HIV-infected patients: a multicenter cohort study
© Ferrer et al; licensee BioMed Central Ltd. 2008
Published: 10 November 2008
Purpose of the study
To assess estimated cardiovascular risk in a population of adult HIV-infected patients.
This is an ongoing, prospective, longitudinal, multicenter cohort study of estimated cardiovascular risk (eCVR). After obtaining informed consent, demographic characteristics, metabolic parameters, and clinical status, including CVR factors, of patients (pts) enrolled from February to August 2006 at 12 Spanish sites were recorded in a central database using an Access data set. eCVR was evaluated by the Framingham equation. For analysis purposes pts were grouped into: 1) low eCVR (< 10% at 10 years); or 2) moderate/high eCVR (> 10%). Descriptive statistics were expressed as median (interquartile range) for quantitative variables and as percentages for qualitative variables. Logistic regression was used to identify the factors that might account for a higher eCVR. Baseline data are presented.
Summary of results
807 pts were included: 73% men, median age 41 (18–83) years, 42% drug users, 26% AIDS, CD4 465/uL, 51% undetectable viral load, 74% taking HAART (51% PI, 49% NNRTI regimens), 64% smokers, 10% hypertension, 5% diabetes, 3.5% coronary or cardiovascular disease (CVD). 81% pts had < 10 eCVR (Grp. 1) and 19% ≥10 eCVR (Grp. 2). Grp. 2 pts were more frequently men, older, non-drug users, smokers, diabetics, hypertensive, had CVD, lipid disturbances, greater waist circumference, greater BMI, undetectable viral load, and used more stavudine and indinavir. On univariate analysis, male sex (OR 8.51), coronary disease (5.77), CVD (3.87), diabetes (3.87), hypertension (3.66), smoking (1.96), age (1.16), lipid alterations (total cholesterol, HDL, LDL, Tryglicerides, no-HDL and TC/HDL, 1.02 to 1.52), waist circumference (1.04), and BMI (1.04) were associated with increased eCVR, while detectable viral load was associated with a low eCVR (0.47). First or current antiretroviral drugs were not associated with increased eCVR. On multivariate analysis, male sex (OR 19.96), age (25.08), smoking (24.12), hypertension (5.41), and total cholesterol (1.04) remained significantly associated with increased eCVR while detectable viral load (0.38) and HDL (0.94) remained significantly associated with a low eCVR.
Traditional cardiovascular risk factors are associated with increased eCVR in our HIV population, and seem to have a stronger role than HAART and HIV infection. Lower eCVR in pts with detectable viral loads is probably related to younger age, lower waist circumference and systolic blood pressure, and a better lipid profile. Pts with higher eCVR may benefit from lipid-friendly ARV therapy, but interventions on life habits are crucial.
This article is published under license to BioMed Central Ltd.